^
    Back
    Association details:
    Biomarker:IDH1 R132C
    Cancer:Cholangiocarcinoma
    Drug:Tibsovo (ivosidenib) (IDH1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

    Excerpt:
    ...- Have documented IDH1 gene-mutated disease based on local testing procedure (R132C/L/G/H/S mutations variants tested)...
    Trial ID:
    NCT05921760
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

    Excerpt:
    ...- Have a documented IDH1 R132C, R132L, R132G, R132H, or R132S gene-mutated disease...
    Trial ID:
    ProvIDHe
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)

    Excerpt:
    ...Have documented IDH1 gene-mutated disease (from a fresh tumor biopsy or the most recent banked tumor tissue available) based on central laboratory testing (R132C/L/G/H/S mutation variants tested)....
    Trial ID:
    ClarIDHy
    Less C2 evidence
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    DGHO 2020
    Title:

    426 - Zielgerichtete Therapie eines IDH1-mutierten Cholangiocarcinoms mit Maffucci Syndrom - ein Fallbericht / First report on the targeted therapy of an IDH1-mutated Cholangiocarcinoma in a patient with Maffucci syndrome

    Published date:
    09/03/2020
    Excerpt:
    Ivosidenib led to a substantial improvement of patient´s overall physical condition and displayed antitumoral activity and tolerable safety profile in a patient with Maffucci syndrome associated CCa.